PALO ALTO, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that the U.S. Food and Drug Administration (FDA) has removed the partial hold on TELCYTA(R) (canfosfamide HCl, TLK286) clinical trials. This action follows a complete review of TELCYTA data by the agency and permits the resumption of TELCYTA clinical development.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidates are TELCYTA, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non- small cell lung cancer; and TELINTRA(R), which is in clinical development for the treatment of myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.
This press release contains "forward-looking" statements, including
statements regarding plans for future clinical development of TELCYTA.
Words such as "will," "plans" and similar expressions are intended to
identify forward-looking statements. These forward-looking statements are
based upon Telik's current expectations. There are important factors that
could cause Telik's results to differ materially from those indicated by
these forward- looking statements, including, among others, that if
clinical trials of TELCYTA are further delayed or unsuccessful, Telik's
business would suffer, and if Telik does not obtain regulatory approval to
market products in the United States and foreign countries, Teli
|SOURCE Telik, Inc.|
Copyright©2007 PR Newswire.
All rights reserved